9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 301–400 of 958
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 21
Mapa, B. D. C., Araújo, L. U., Silva-Barcellos, N. M., Caldeira, T. G., & de Souza, J. (2020) · Applied Sciences · doi:10.3390/app10207131 · Cited by 20
Long, J., Liu, Y., Duan, Y., Li, Y., Yang, G., Ren, Z., Wei, T., & Liu, D. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03225-7 · Cited by 20
Persistent disparities in diabetes medication receipt by socio‐economic disadvantage in Australia
Morton, J. I., Ilomäki, J., Magliano, D. J., & Shaw, J. E. (2022) · Diabetic Medicine · doi:10.1111/dme.14898 · Cited by 20
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 22
Rakesh, G., Cordero, P., Khanal, R., Himelhoch, S. S., & Rush, C. R. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.037 · Cited by 21
Essien, U. R., Tang, Y., Figueroa, J. F., Litam, T. M. A., Tang, F., Jones, P. G., Patel, R. B., Wadhera, R. K., Desai, N. R., Mehta, S. N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1178 · Cited by 20
Chadha, M. D., Jain, S. M., Chawla, R., Dharmalingam, M., Chaudhury, T., Talwalkar, P., Tripathi, S., Singh, S., Gutch, M., & Dasgupta, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230116150205 · Cited by 20
“However, in the 2020 guidelines, the upper limit of basal insulin has been modified to >0.5 U/kg/day [6].”
BackgroundInfluentialKatsiki, N., Ferrannini, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154218 · Cited by 20
Lawrence, W. R., Hosler, A. S., Gates, M. A., Leinung, M. C., Zhang, X., Schymura, M. J., & Boscoe, F. P. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101710 · Cited by 20
Zhou, J., Pan, J., Xiang, Z.-N., Wang, Q., Tong, Q., Fang, J., Wan, L.-S., & Chen, J. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113098 · Cited by 20
Moon, J. S., Suh, S., Kim, S. S., Jin, H. Y., Kim, J. M., Jang, M. H., Lee, J. H., Lee, J. H., Chung, S. M., Lyu, Y. S., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0107 · Cited by 20
Gedawy, A., Al‐Salami, H., & Dass, C. R. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0102 · Cited by 19
Cheong, M., Chew, S. T. H., Oliver, J. S., Baggs, G. E., Low, Y. L., How, C. H., Tan, N. C., Huynh, D. T. T., & Tey, S. L. (2020) · Nutrients · doi:10.3390/nu12113329 · Cited by 24
SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
Салухов, В. В., Khalimov, Y. S., Борисович, Ш. С., & Popov, S. I. (2021) · Diabetes Mellitus · doi:10.14341/dm12123 · Cited by 22
Ando, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Joubert, M., Meyer, L., Doriot, A., Dreves, B., Jeandidier, N., & Reznik, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01082-2 · Cited by 19
Tittel, S. R., Laubner, K., Schmid, S. M., Kress, S., Merger, S. R., Karges, W., Wosch, F. J., Altmeier, M., Pavel, M., Holl, R. W., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13215 · Cited by 19
Delivery of miRNAs to the adipose organ for metabolic health
Kornmueller, K., Amri, E., Scheideler, M., & Prassl, R. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114110 · Cited by 20
Telemedicine for the management of diabetic patients in a high-complexity Latin American hospital
Casas, L. Á., Alarcón, J., Urbano, A., Peña-Zárate, E. E., Sangiovanni, S., Libreros‐Peña, L., & Escobar, M. F. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09267-0 · Cited by 20
Imai, T., Kato, N., Kanda, N., Hashimoto, H., Yamana, H., & Hatakeyama, S. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01613-7 · Cited by 18
Chung, W.-S., Le, P., Kuo, C. J., Chen, T., Kuo, C., Chiou, M., Chou, W., Yeh, T., & Hsu, J. (2020) · Cancers · doi:10.3390/cancers12082013 · Cited by 18
Goderis, G., Vaes, B., Mamouris, P., Craeyveld, E. V., & Mathieu, C. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1508-3912 · Cited by 19
Fathi, A. E., Fabris, C., & Breton, M. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795895 · Cited by 19
Attimarad, M., Venugopala, K. N., Chohan, M. S., David, M., Molina, E. I. P., Sreeharsha, N., Nair, A. B., Tratrat, C., Altaysan, A. I., & Balgoname, A. A. (2022) · Molecules · doi:10.3390/molecules27103135 · Cited by 20
Kalra, S., Das, S., & Zargar, A. H. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_522_21 · Cited by 24
Teo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
Patient preferences for newer oral therapies in type 2 diabetes
Savarese, G., Sharma, A., Pang, C., Wood, R., & Soleymanlou, N. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.009 · Cited by 19
Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
Bays, H. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100003 · Cited by 20
Yang, L., Gabriel, N., Hernandez, I., Winterstein, A. G., & Guo, J. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5206 · Cited by 17
Hanson, P., Randeva, H. S., Cuthbertson, D. J., O'Hare, P. J., Parsons, N., Chatha, K. K., Reidy, G., Weickert, M. O., & Barber, T. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.381 · Cited by 17
Shi, F., Li, H., Yue, J., Jiang, Y., Gu, Z., Ma, J., & Lin, H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa586 · Cited by 19
Zhao, B., Shen, J., Zhao, J., & Pan, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13481 · Cited by 18
Naing, S., Ramesh, G., Garcha, J., Poliyedath, A., Khandelwal, S., & Mills, P. K. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.204 · Cited by 17
Lingvay, I., Greenberg, M., Gallo, S., Shi, H. H., Liu, J., & Gantz, I. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14385 · Cited by 17
Cardiovascular benefit of SGLT2 inhibitors
Mohebi, R., & Januzzi, J. L. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1993439 · Cited by 17
Ciardullo, S., Cannistraci, R., Mazzetti, S., Mortara, A., & Perseghin, G. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.02.037 · Cited by 17
Diabetes in Kidney Transplantation
Cantarin, M. P. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.10.004 · Cited by 18
Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin
Li, S., Xu, B., Fan, S., Kang, B., Deng, L., Chen, D., Yang, B., Tang, F., He, Z., Xue, Y., et al. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2118714 · Cited by 19
Chivardi, C., Hutchinson, B. W., Molina, V., Moreno, E., Fajardo, I., Arcila, G. P. G., Serrano, H. M. M., Ordúñez, P., Rodríguez-Franco, R., Moran, A. E., et al. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.144 · Cited by 17
Diabetes Mellitus and Heart Failure
Siao, W.-Z., Chen, Y.-H., Tsai, C., Lee, C.-M., & Jong, G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101698 · Cited by 18
Meta‐analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus
Mahmoud, F., Mullen, A. B., Sainsbury, C. A. R., Rushworth, G. F., Yasin, H., Abutheraa, N., Mueller, T., & Kurdi, A. B. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.13997 · Cited by 19
“75,77,78 This might positively reflect clinical practice adherence to drug characteristics when prescribing metformin to older patients with T2DM.”
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Pilla, S. J., Kraschnewski, J. L., Lehman, E. B., Kong, L., Francis, E., Poger, J. M., Bryce, C. L., Maruthur, N. M., & Yeh, H.-C. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002153 · Cited by 16
Wharton, S., Yin, P., Burrows, M., Gould, E. M., Blavignac, J., Christensen, R. A. G., Kamran, E., Camacho, F., & Barakat, M. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00831-4 · Cited by 17
Chang, Z., Xu, J., Qin, Y., Zheng, Q., Zhao, L., Wang, Y., & Zhang, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282143 · Cited by 17
García-Zamora, M., García‐Lluch, G., Moreno, L., Pardo, J., & Cháfer-Pericas, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107295 · Cited by 16
Castellana, M., Procino, F., Sardone, R., Trimboli, P., & Giannelli, G. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001477 · Cited by 19
Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease
Escott, G. M., da Silveira, L. G., Cancelier, V. D. A., Dall’Agnol, A., & Silveiro, S. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107774 · Cited by 17
Scisciola, L., Rizzo, M. R., Marfella, R., Cataldo, V., Fontanella, R. A., Boccalone, E., Paolisso, G., & Barbieri, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30185 · Cited by 16
Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Hearn, E. B., & Sherman, J. J. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0033 · Cited by 16
Fujihara, K., Matsubayashi, Y., Yamada, M. H., Yamamoto, M., Iizuka, T., Miyamura, K., Hasegawa, Y., Maegawa, H., Kodama, S., Yamazaki, T., et al. (2021) · JMIR Medical Informatics · doi:10.2196/22148 · Cited by 17
Newman, T. V., Munshi, K. D., Neilson, L. M., Good, C. B., Swart, E. C. S., Huang, Y., Henderson, R. R., & Parekh, N. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.4.435 · Cited by 19
Pharmacogenetics of new classes of antidiabetic drugs
Imamović, S., Kulo, A., & Dujić, T. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.5646 · Cited by 24
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes
Doupis, J., Baris, N., & Avramidis, K. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.88 · Cited by 16
Damianaki, A., Polychronopoulou, E., Wuerzner, G., & Burnier, M. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00495-1 · Cited by 20
“The multiple properties of the new classes of glucose-lowering medications, such as sodium-glucose transporter 2 inhibitors (SGLT2i) and GLP1 receptor agonists, intensified the research for their implementation in the setting of the management of diabetic and non-diabetic kidney diseases.”
BackgroundInfluentialLuo, J., Gabriel, N., Korytkowski, M. T., Hernandez, I., & Gellad, W. F. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109855 · Cited by 16
Shou, X., Wang, Y., Duan, C., Yuan, G., Wei, N., Yang, Y., & Hu, Y. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101194 · Cited by 18
Chou, M.-Y., Huang, S., Liang, C., Peng, L., Lin, Y., Hsiao, F., & Chen, L. (2021) · Age and Ageing · doi:10.1093/ageing/afab183 · Cited by 16
Xie, D., Zhu, Y., Guo, S., Li, H., Wang, Z., Wang, X., Cai, Y., Chai, J., Wang, Y., Hu, Z., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01152-7 · Cited by 17
“Several guidelines 7 – 9 , including the American Diabetes Association (ADA), recommend metformin as the fi rst-line hypoglycemic agent for patients with T2DM or DKD. Metformin ameliorates hyperglycemia by inhibiting”
Łuniewski, M., Matyjaszek‐Matuszek, B., & Lenart-Lipińska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134431 · Cited by 16
Role of Oxidative Stress in Tuberculosis Meningitis Infection in Diabetics
Navasardyan, I., Yeganyan, S., Nguyen, H., Vaghashia, P., Subbian, S., & Venketaraman, V. (2023) · Biomedicines · doi:10.3390/biomedicines11092568 · Cited by 18
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Kim, K., Hong, S., Ahn, H. Y., & Park, C. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00948-1 · Cited by 15
Flores‐Hernández, S., Acosta-Ruíz, O., Hernández-Serrato, M. I., Delgado-Rodríguez, S., & Reyes‐Morales, H. (2020) · Salud Pública de México · doi:10.21149/11876 · Cited by 15
Olufade, T. O., Jiang, L., Israni, R., Huang, J., & Gosmanov, A. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14530 · Cited by 17
Wu, Q., Liao, C., He, M., Li, C., Zou, F., Hu, L., Wei, Y., & Zhang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13521 · Cited by 15
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos, R. D., & Stein, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00515-4 · Cited by 18
Attimarad, M., Venugopala, K. N., Nair, A. B., Sreeharsha, N., Molina, E. I. P., Kotnal, R. B., Tratrat, C., Altaysan, A. I., Balgoname, A. A., & Deb, P. K. (2022) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2022.121303 · Cited by 15
Vohra, M., Sharma, A., Mallya, S. D., Prabhu, N. B., Jayaram, P., Nagri, S. K., Umakanth, S., & Rai, P. S. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01989-y · Cited by 15
Mishriky, B. M., Okunrintemi, V., Jain, S., Sewell, K. B., Powell, J. R., & Cummings, D. M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.002 · Cited by 15
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Ouwens, D. M., Hartmann, B., Holst, J. J., Touw, D. J., Danser, A. H. J., Joles, J. A., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0902 · Cited by 16
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.06.009 · Cited by 17
Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview
Guo, Z., & Priefer, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102239 · Cited by 17
Association Between Colonic 18F-FDG Uptake and Glycemic Control in Patients with Diabetes Mellitus
Chang, H. S., Kim, S. J., & Kim, Y. H. (2020) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-020-00647-6 · Cited by 14
Alkhezi, O. S., Alsuhaibani, H. A., Alhadyab, A. A., AlFaifi, M., Alomrani, B., Aldossary, A., & Alfayez, O. M. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.04.005 · Cited by 14
Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Diabetes Care · doi:10.2337/dc22-0712 · Cited by 14
Kaufmann, G. T., Hyman, M. J., Gonnah, R., Hariprasad, S. M., & Skondra, D. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.11.22 · Cited by 16
The influence of stress and coping on diabetes self-care activities among college students
Thomas, J. J., Moring, J. C., Bowen, A. M., Rings, J. A., Emerson, T., & Lindt, A. (2021) · Journal of American College Health · doi:10.1080/07448481.2021.1928142 · Cited by 14
Heerspink, H. J. L., Law, G., Psachoulia, K., Connolly, K., Whatling, C. A., Ericsson, H., Knöchel, J., Lindstedt, E., & MacPhee, I. A. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.08.018 · Cited by 14
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“Liraglutide was found to be protective against angiotensin II– and pressure overload–induced cardiac hypertrophy via PI3K/Akt1 and AMPK α signaling in mice (43).”
Kawaguchi, Y., Sawa, J., & Kumeda, Y. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00940-9 · Cited by 14
Qiao, H., Li, Y., Xu, B., Lu, Z., Zhang, J., Meng, D., He, S., & Huang, J. (2022) · Cardiology · doi:10.1159/000527384 · Cited by 13
Laursen, H. V. B., Jørgensen, E. P., Vestergaard, P., & Ehlers, L. H. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01268-5 · Cited by 14
Gao, X., Zhang, N., Lü, L., Gao, T., Chou, O. H. I., Wong, W. T., Chang, C., Wai, A. K. C., Lip, G. Y. H., Zhang, Q., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad086 · Cited by 13
Bzowyckyj, A. S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13229 · Cited by 14
Bae, J., Huh, J. H., Lee, M., Lee, Y., & Lee, B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14259 · Cited by 13
Mohammadi, E., Sadeghi, F., Roshani, S., Rezaei, N., Azadnajafabad, S., Moghaddam, S. S., Azmin, M., Karimian, M. S., Fattahi, N., Jamshidi, K., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00663-5 · Cited by 13
Race and sex differences in the initiation of diabetes drugs by privately insured US adults
McCoy, R. G., Houten, H. K. V., Dunlay, S. M., Yao, X., Dempsey, T. M., Noseworthy, P. A., Sangaralingham, L. R., LIMPER, A. H., & Shah, N. D. (2021) · Endocrine · doi:10.1007/s12020-021-02710-4 · Cited by 13
Vlacho, B., Mata‐Cases, M., Mundet, X., Callol, J.-A. V. I., Real, J., Farré, M., Cos, X., Khunti, K., Mauricio, D., & Franch‐Nadal, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.708372 · Cited by 14
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
Lee, S. E., Nam, H., Choi, H. S., Kim, H., Kyoung, D., & Kim, K. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0160 · Cited by 14
George, J., Lobkovich, A. M., Nardolillo, J. A., Farhat, N., Kolander, S., & Thomas, E. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac046 · Cited by 13
Continuity of Medication Use by US Adults With Diabetes, 2005-2019
Chehal, P. K., Uppal, T. S., Turbow, S. D., Fernandes, G. F., HAW, J. S., Shah, M. K., Rajpathak, S. N., Narayan, K. M. V., & Ali, M. K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53562 · Cited by 13
Liu, Y., Li, W., Chen, Y., & Wang, X. (2023) · Endocrine · doi:10.1007/s12020-023-03499-0 · Cited by 14
“Currently, insulin administration is regarded as the cornerstone treatment for individuals with T1D [5].”
COX2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study
Tan, G. S. Q., Morton, J. I., Wood, S. J., Trevaskis, N. L., Magliano, D. J., Windsor, J. A., Shaw, J. E., & Ilomäki, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111082 · Cited by 13
Home, P. D., Aroda, V. R., Blonde, L., Guyot, P., Shaunik, A., Fazeli, M. S., Goswami, H. H., Kalra, S., & Pourrahmat, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14136 · Cited by 14
Lavernia, F., & Blonde, L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798638 · Cited by 13
Budoff, M. J., Davis, T. M. E., Palmer, A. G., Frederich, R. C., Lawrence, D. E., Liu, J., Gantz, I., & Derosa, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01033-x · Cited by 13
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.